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Abstract
Introduction: Financial incentives increase smoking abstinence among pregnant
and postpartum women. They have also been reported to reduce psychological symptoms
using the Beck Depression Inventory (BDI) and Brief Symptom Inventory (BSI) in
women at risk for perinatal depression. This prospective study aims to replicate and
extend these findings using the BDI and Edinburgh Postpartum Depression Scale
(EPDS). Methods: Participants were 169 pregnant cigarette smokers who were assigned
to one of two treatment conditions: Best Practices only (n=88), which entails brief
counseling and a referral to a pregnancy-specific quit-line, or Best Practices + Incentives
(n=81). Participants were categorized as at increased risk (Dep+; n= 91) or lower risk
(Dep-; n= 76) for depression based on history of depressive symptoms and baseline
symptom scores. Treatment effects on smoking status and BDI/EPDS scores were
examined across nine perinatal assessments using repeated measures analyses of
covariance. Results: Financial incentives increased rates of biochemically-verified
abstinence through 12-weeks postpartum independent of depression risk (ps ≤ .01) but
did not differentially decrease BDI or EPDS scores (ps > .05). Scores decreased with both
interventions for the Dep+ women (p = .001). Conclusions: These results replicate
earlier evidence that financial incentives increase perinatal smoking abstinence in Dep+
women but not their efficacy in differentially reducing depressive symptoms at levels
greater than Best Practices. The failure to replicate effects on depressive symptoms may
be due to use of different control conditions in the current and prior study or increased
screening and intervention for perinatal mental health during routine obstetrical care.

Key terms: financial incentives, contingency management, cigarette smoking, smoking
cessation, postpartum, perinatal, depression, Edinburgh Postnatal Depression Scale
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Introduction
Smoking During the Perinatal Period
Cigarette smoking during pregnancy is the leading preventable cause of poor
pregnancy outcomes in the U.S. and other developed countries (Chamberlain et al., 2013;
Einarson & Riodan, 2009, Espy et al., 2011; U.S. Department of Health and Human
Services, 2014). Rates of women smoking during pregnancy in the U.S. have decreased
over the past decade although that encouraging trend appears to have leveled off in the
past few years (Kurti et al., 2018a; Meernik & Goldstein 2015; Tong et al., 2013). The
most recent study on smoking prevalence during pregnancy in a U.S. nationally
representative sample noted a prevalence rate of 13.8% (Kurti et al., 2018a). However,
rates of smoking during pregnancy are higher in at-risk groups (e.g., women with
psychiatric conditions, younger age, low educational attainment, Medicaid or other public
health insurance), with some research reporting rates of smoking in disadvantaged
populations exceeding 20% (Curtin & Mathews, 2016; Oncken et al., 2012; Tong et al.,
2013).
Despite general knowledge about the dangers of perinatal smoking and an
expressed desire to quit, many women are unable to do so. A recent report indicated that
approximately 53.4% of women reported quitting during pregnancy; however other
studies have reported rates closer to 25% (Kurti et al., 2018b; Orton et al., 2017; Riaz et
al., 2017; Tong et al., 2009). What is clear is that a substantial proportion of pregnant
women fail to quit smoking during pregnancy and among those that do, 50-75% resume
smoking within the first year postpartum (Orton et al., 2017; Riaz et al., 2017; Tong et
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al., 2009). These statistics highlight the need for efficacious treatments targeting smoking
cessation in the perinatal period, particularly for high-risk women.
Risk factors.
The most commonly reported risk factors associated with continued smoking
during pregnancy include lower socioeconomic status—especially lower education,
experiencing psychological distress (e.g., depressive or anxious symptoms or high levels
of stress), younger age, being Caucasian, having multiple children, living with someone
who smokes, and ambivalence about quitting (Coleman-Cowger et al., 2015; Kurti et al.,
2018a; Orton et al., 2017; Riaz et al., 2017). Other factors also include higher nicotine
dependence, younger age of initiation, single marital status, other substance use, cravings,
and using smoking as a coping mechanism for stress (Coleman-Cowger et al., 2015;
Orton et al., 2017). Overall, the most significant risk factors for continued smoking
during pregnancy in the U.S. include low socioeconomic status, being Caucasian, and
psychological distress (Coleman-Cowger et al. 2015; Kurti et al., 2018a).
The most commonly reported risk factors associated with postpartum relapse
include the above factors, as well as not breastfeeding, only intending to quit during
pregnancy, low confidence about remaining abstinent postpartum, and quitting later in
pregnancy (Orton et al., 2017). Across the perinatal (i.e., during pregnancy and following
childbirth), the most significant risk factors for smoking are low socioeconomic status,
especially low educational attainment, and psychological symptoms.
Adverse outcomes associated with smoking in the perinatal.
Perinatal smoking is associated with a multitude of adverse health effects for
mother and offspring. Negative birth-related outcomes associated with smoking during
2

pregnancy include miscarriage, placental abruption, fetal growth retardation, low
birthweight, and premature delivery (Abraham et al., 2010; Chamberlain et al., 2013;
Einarson & Riodan, 2009, Espy et al., 2011; Jonas et al., 2012; Patnode et al., 2015;
Talati et al., 2017; U.S. Department of Health and Human Services, 2014). Additional
adverse outcomes include cognitive impairments in neonates exposed to maternal
smoking in utero (Espy et al., 2011). Timing of smoking during pregnancy appears to be
a factor associated with increased risk of adverse birth outcomes with women who
continue smoking into their third trimester being at greatest risk for decrements in infant
birth weight and length compared to women who were able to quit earlier in their
pregnancies (Espy et al., 2011). These deleterious effects are exacerbated by heavier
smoking (Espy et al., 2011; Kharkova et al., 2017; Mei-Dan et al., 2015). Additional
adverse effects include increased risk for externalizing disorders, childhood respiratory
diseases, congenital anomalies, increased body mass index, increased risk for metabolic
disorders, and mood disorders (e.g., Abraham et al., 2010; Banderali et al., 2015; Bhat et
al., 2018; Chamberlain et al., 2013; Einarson & Riodan, 2009; Jonas et al., 2012; Patnode
et al., 2015; Talati et al., 2017; U.S. Department of Health and Human Services, 2014).
Further, offspring of women who smoke during pregnancy may experience social, and
developmental delays (Abraham et al., 2010; Jonas et al., 2012; Patnode et al., 2015).
It appears that nicotine’s effects on the fetus occur through crossing the placental
barrier and altering cholinergic nicotinic receptors’ sensitivity in the developing fetal
brain (Talati et al., 2017). This altering of sensitivity impacts dopaminergic, serotonergic,
and norepinephrine systems (Campos et al., 2016; Espy et al., 2011). These systems play
a role in attention and executive function, in addition to motor, sensory, and emotional
3

development. Thus, chronic in-utero nicotine exposure can negatively impact the
development and functioning of these systems and impact the offspring in a multitude of
ways over the life-course (Campos et al., 2016; Malone et al., 2003). These biological
factors highlight the pervasive negative impact that perinatal smoking has on offspring.
Postpartum smoking is associated with still other adverse effects on offspring, as
second-hand smoke increases exposure to carcinogens which can have long-term
deleterious health effects. Postpartum smoking has been linked to Sudden Infant Death
Syndrome, pneumonia and other respiratory diseases, and middle ear infections (U.S.
Office on Smoking and Health, 2006; U.S. Department of Health and Human Services,
2014). Mechanisms by which second-hand smoke impacts child health are not fully
understood; however, impairment of the development of airways and other important
systems may play a role, in addition to the offspring’s body adjusting to chronic exposure
and having overactive or underactive biological systems (e.g., bronchial hyperactivity,
increases in neuroendocrine cells, overactive central nervous system reflexes, inhibition
of immune system response, cardiorespiratory control deficiencies; U.S. Office on
Smoking and Health, 2006). Refer to the Surgeon General’s report for an in-depth review
of potential mechanisms (U.S. Office on Smoking and Health, 2006).
In addition to the negative impact on offspring, smoking in the perinatal is also
associated with adverse effects for mothers, including exacerbated mental health
symptoms, cervical cancer, and osteoporosis (Gadducci et al., 2011; Roth & Taylor,
2001). More specifically, women who smoke prior to or during pregnancy endorse higher
levels of mood disturbance (e.g. elevated anxious and depressive symptoms) compared to
women who do not smoke (e.g., Coleman- Cowger et al., 2016; DeWilde et al., 2013).
4

More information regarding the interaction of smoking and mood symptoms will be
discussed below. Briefly focusing on the most devasting impact of smoking in relation to
mood, smoking during the perinatal has been linked to increased risk of maternal suicide
attempts (Farias et al., 2013; Schiff & Grossman, 2006; Tavares et al., 2012). One study
found that 57.14% of those endorsing a perinatal suicide attempt actively smoked during
pregnancy and that tobacco use during pregnancy was independently associated with
suicide attempts (Gressier et al., 2017). Overall, the adverse impact of perinatal smoking
during for mother and child highlights the need for interventions targeting smoking
during this critical period.
Perinatal Depressive Symptoms
Beyond smoking, perinatal psychological symptoms can also have a negative
impact on mother and child. In general, women have two to three-times higher
prevalence rates of depressive symptoms in comparison to men (Abate, 2013;
Cyranowski et al., 2000; Ford & Erlinger, 2004; Gutierrez-Lobos et al., 2002; Sloan &
Kornstein, 2003). Further, the perinatal period is considered a heightened risk period for
the development of depressive symptoms in women and the time of onset plays a role in
symptom severity. Approximately 10-20% of U.S. women develop perinatal depression,
with one study reporting that approximately 20% experiencing depressive symptoms that
begin during pregnancy and another study reporting that approximately 15% developing
symptoms in the postpartum (American Congress of Obstetricians and Gynecologists,
2015; Cantwell & Cox, 2006; Gressier et al., 2017; Goodman, 2007; O’Hara & McCabe,
2013 Pampaka et al., 2018). However, timing is important as women experiencing
psychological symptoms starting antepartum exhibit more severe postpartum depressive
5

symptoms than those with a postpartum onset (PACT Consortium, 2015). For many
women, perinatal depressive symptoms are “time-limited” and resolve within the first
year postpartum, but for approximately 38% of women, these symptoms develop into a
more chronic, persistent disorder (Haga et al., 2012; Vliegen et al., 2014).
Perinatal depression is formally defined as the experience of a major depressive
episode with onset during pregnancy or within 4 weeks postpartum utilizing the “with
perinatal onset” specifier in the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5; APA, 2013). In order to receive a diagnosis of major depressive episode with
perinatal onset, five symptoms in the diagnostic criteria must be met for at least two
weeks, one of which must include either depressed mood or lack of pleasure, also
referred to as anhedonia. Other symptoms necessary to meet diagnostic criteria include:
changes in sleep, changes in appetite or weight, psychomotor agitation or retardation, loss
of energy, diminished ability to think or concentrate, feelings of worthlessness or
inappropriate guilt, and suicidal ideation (APA, 2013). There is some debate about the
time-limited qualifier for perinatal onset listed in the DSM-5 and there is discrepancy
between different diagnostic entities. For example, the International Classification of
Diseases (ICD-10; World Health Organization, 1992) has a longer time period lasting
during pregnancy through 6-weeks postpartum. Researchers and advocates for those
suffering with perinatal depression have called for extensions of this timeline all the way
out to 6-months postpartum (Sharma & Xie, 2010; Segre & Davis, 2013; Wisner et al.,
2010).
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Risk factors.
Regardless of time of onset and duration of symptoms, the most frequently
reported psychosocial risk factors for perinatal depression include: a history of affective
disorders, particularly depression and anxiety; a history of psychological distress in prior
pregnancies and postpartum; lack of perceived social support; low socioeconomic status;
stress and adverse life events, especially during pregnancy; being unmarried; having an
unwanted or unplanned pregnancy; low self-esteem; and a history of substance use (e.g.,
Cantwell & Cox, 2006; Drozd et al., 2018; English et al., 2018; Fredriksen et al., 2017).
Although all of these risk factors are important, some risk factors may more effectively
predict the development of depressive symptoms. Across a multitude of studies and
systematic reviews, the most significant risk factors for perinatal depressive symptoms
include a personal history of psychological disorders, specifically anxious and depressive
symptoms, and lack of perceived social support (e.g., Alves et al., 2018; Cantwell & Cox,
2006; Drozd et al., 2018; English et al., 2018; Evagorou et al., 2016; Fredriksen et al.,
2017; Leung et al., 2006; McCall-Hosenfeld et al., 2016; Pampaka et al., 2018). These
risk factors are observed in different populations and across Westernized and nonWesternized cultures (English et al., 2018; Evagorou et al., 2016; Fredriksen et al., 2017).
Expanding on the risk factor of psychological symptoms for the development of
perinatal disorders, psychological stress and symptoms (i.e. anxious and depressive) have
been extensively linked to perinatal depression (English et al., 2018; Fredriksen et al.,
2017; Milgrom et al., 2008). More specifically, the risk of developing perinatal
depression is 20 times higher for women with versus without a history of depression
(whether experienced generally or in prior pregnancies; (English et al., 2018; Fredriksen
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et al., 2017). Importantly for this project, women who report cigarette smoking or other
substance use are at increased odds of developing perinatal depressive symptoms and
continued smoking during pregnancy is associated with worsening mental health
symptoms (Connelly et al., 2013; Fredriksen et al., 2017; Schroeder et al., 2010).
Biological factors associated with pregnancy are also deemed to play a role in the
development and maintenance of perinatal depressive symptoms (Bloch et al., 2003;
Evagorou et al., 2016; Farris et al., 2018; Hillerer et al., 2012). Dysregulation of the stress
response system due to hormonal fluctuations and chronic stress can lead to the onset or
exacerbation of depressive symptoms (Brummelte et al., 2010; Hillerer et al., 2012).
Notably, sensitivity to these hormonal fluctuations and increased stress levels may occur
more frequently for disadvantaged women (Brummelte et al., 2010; Hillerer et al., 2012).
Some studies have noted that lower oxytocin levels in pregnancy, due to stress, substance
use, or other factors, also increases risk for postpartum symptoms (Hillerer et al., 2012;
Skrundz et al., 2011). The sudden drop in hormonal levels following delivery has also
been linked to onset of postpartum depressive symptoms (Bloch et al., 2003; Hillerer et
al., 2012). Beyond hormones, other biological factors, namely complications during or
following birth (e.g., emergency caesarean section, complicated labor, trouble
breastfeeding) can increase the likelihood of developing postpartum depressive
symptoms (Drozd et al., 2018). Importantly, these biological factors can be exacerbated
by other risk factors. For example, women already at heightened risk for depression due
to psychosocial factors may be more sensitive to hormone fluctuations during the
perinatal period or be less able to cope with complications during labor and delivery,
increasing risk for perinatal depression (Brummelte et al., 2010).
8

Adverse outcomes associated with depressive symptoms in the perinatal.
Untreated perinatal depressive symptomatology can have deleterious effects for
mother and infant. Higher risk for psychological disorders, problematic attachment styles,
and impaired cognitive, motor, and social development in the offspring are linked to
perinatal depressive symptoms (e.g., Almeida et al., 2012; Brummelte et al., 2010;
Gressier et al., 2017; Khalifa et al., 2018; Pampaka et al., 2018; Prenoveau et al., 2017).
Further, the physical health of the infant may be jeopardized as mothers with postpartum
depression are less likely to attend well-baby and immunization visits and more likely to
utilize emergency services (Minkovitz et al., 2005; Pampaka et al., 2018). Maternal
depressive symptoms have predicted poorer infant health in the first two years of life
(Khalifa et al., 2018; Krause et al., 2018).
Perinatal depression also adversely impacts the mother and is linked to increased
marital difficulties, increased likelihood of engaging in unhealthy behaviors (e.g.,
drinking, smoking, poor nutrition), increased risk of suicide, and exacerbation of other
psychological symptoms (e.g., Almeida et al., 2012; Brummelte et al., 2010; Gressier et
al., 2017; Khalifa et al., 2018; Pampaka et al., 2018; Prenoveau et al., 2017).
Approximately 20% of perinatal deaths are attributable to suicide and it is the
second most common cause of mortality among women during this time period (Lindahl,
Pearson, & Colpe, 2005). Among women endorsing perinatal depressive symptoms, one
in three report self-harm (Mauri et al., 2012). One study noted that approximately 24% of
their sample with a history of depressive symptoms endorsed attempted suicide in the
perinatal (Healey et al., 2013). Another study examining a larger cohort found similar
rates, with rates of suicidal ideation, attempts, or completion of 18.4%-26.4% in
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pregnancy and 30.6%- 34.1% postpartum for women with depressive symptoms (Mauri
et al., 2012). Rates were dramatically lower for women without depressive
symptomatology, with 6.9% in pregnancy and 4.3% postpartum endorsing suicidality
(Mauri et al., 2012). The potentially devastating impact of untreated depressive
symptoms highlights the need for interventions to address these symptoms during this
critical time period.
In a literature review examining interventions targeting postpartum depression,
approximately one-third of women categorized as at risk for depression did not
experience a full onset of a major depressive episode in the perinatal due to early
identification and intervention (Dennis & Dowswell, 2013). These findings suggest that
symptoms and associated negative effects can be detected, addressed, and ameliorated
throughout the perinatal. This review and the adverse effects for both mother and child
listed above highlight the need for interventions which mitigate maternal psychological
distress during this sensitive time period.
Smoking and Mood
The interaction of smoking and mood symptomatology is a bidirectional
relationship. As mentioned in the prior sections, smoking is associated with exacerbated
psychological distress and perinatal depressive symptoms have been associated with
smoking. We next examine the impact that depressive symptoms have on smoking in the
perinatal and then discuss the relationship in the opposite direction, examining the impact
of smoking on psychological symptoms.
In the general population, depressive symptoms are associated with increased
likelihood of smoking, heavier smoking, and greater difficulty quitting (Lasser et al.,
10

2000; Leventhal et al., 2014; Mathew et al., 2017; Stepankova et al., 2017). Depressive
symptoms are also associated with diminished confidence in ability to quit and more
ambivalence about changing habits, particularly in women (Johnson et al., 2017). Adults
with psychological symptomatology represent approximately 25% of the U.S. population
and are twice as likely to be smokers compared to those without psychological symptoms
(Lasser et al., 2000). Smokers represent a large portion of those experiencing
psychological distress, with approximately 36.1% of adults with psychological symptoms
reporting smoking (CDC, 2013). Additionally, smokers with psychological
symptomatology smoke at higher rates than those without symptoms and consume
approximately 44% of the nation’s cigarettes per year (Lasser et al., 2000; Satcher et al.,
2000). Finally, smokers with depressive disorders are more likely to be lifetime smokers
(Lasser et al., 2000; Stepankova et al., 2017). These findings highlight the intensity of
cigarette consumption and nicotine dependence observed among adults experiencing
psychological distress.
The association between depressive symptoms and smoking is also found when
examining women during the perinatal period. Women with previous depressive and
anxious symptomatology are 1.5-2.5 times more likely to smoke during pregnancy (CDC,
2016; Goodwin et al., 2017; Tong et al., 2016) and approximately 15% less likely to quit
(Tong et al., 2016). Approximately one in ten women with prior symptoms continue to
smoke in the third trimester (CDC, 2016).
Considering the reciprocal relationship between depressive mood and smoking
from the other direction, continued smoking has been reported to exacerbate mental
health conditions among smokers generally (Schroeder & Morris, 2010). Nicotine
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dependence and heavier smoking are associated with greater depression severity and a
slower recovery (Chase et al., 2018; Jamal et al., 2012). In addition to the bidirectional
relationship observed between smoking and depressive symptoms, many of the risk
factors for continued smoking during pregnancy and depressive symptoms overlap (e.g.,
chronic socioeconomic disadvantage, perceived life stress; Correa et al., 2015; Walker et
al., 2016). For example, perceived stress can play a role in maintaining smoking during
pregnancy or relapse back to smoking postpartum among those who use smoking as a
coping strategy (Ansel et al., 2012; Correa et al., 2015). Stress sensitivity and stressors
themselves can also lead to the onset or maintenance of perinatal depressive symptoms,
particularly if the woman perceives that she has little social support (Beck et al., 2001;
Corrigan et al., 2015). These common risk factors can contribute to this bidirectional
relationship, and simultaneously both exacerbate depressive symptoms and contribute to
the maintenance of smoking.
A learning theory perspective.
A learning theory framework may help to elucidate the bidirectional relationship
between smoking and depressive symptoms. From this perspective, depressive symptoms
are related to factors which exacerbate risk for smoking such as a relatively low density
of non-drug reinforcers, difficulty engaging in goal-directed behavior, and decreased use
of adaptive coping strategies when stressed (e.g., Atherton et al., 2015; Chase et al.,
2018). Difficulty engaging in goal-directed behavior under stress and increased valuation
of cigarettes is associated with attentional biases for smoking, positive expectancies
regarding the reinforcing value of cigarettes, increased motivation to smoke, and
increased likelihood of continued smoking even if trying to quit (Chase et al., 2018;
12

Farris et al., 2015). Smokers with depressive symptoms endorse having higher
expectations for the reinforcing value of cigarettes and greater relative reward value for
smoking (Guillot et al., 2017; Chase et al., 2018; Mathew et al., 2017; Spring et al., 2003;
Tidey et al., 2008).
Depressive symptoms are associated with a blunted response to non-drug stimuli
and overvaluation of cigarettes compared to other reinforcers (Guillot et al., 2017;
Mathew et al., 2017). It appears that through repeated exposure (e.g., continued
smoking), the reinforcing value of cigarettes increases. Over time, smokers with
depressive symptoms develop an imbalance in the reinforcing value of cigarettes
compared to other reinforcers. This overvaluation of cigarettes has been consistently
linked to increased consumption, craving, withdrawal, and relapse risk (Cook et al., 2010;
Leventhal et al., 2008; Leventhal et al., 2014; Zvolensky et al., 2009). The overvaluation
of cigarettes compared to other reinforcers is evidenced by higher withdrawal symptoms
among smokers with depressive symptoms and endorsement of higher positive affect and
reward responsivity when smoking following acute withdrawal (Cook et al., 2007;
Mathew et al., 2017). Further, smokers experiencing anhedonia (i.e., decreased capacity
to experience positive reinforcement) report feeling more positive affect after smoking
cigarettes compared to their non-depressed counterparts, and thus, may be more likely to
smoke in response to negative emotional states (Cook et al., 2007; Mathew et al., 2017).
The blunted response to non-drug stimuli and overvaluation of cigarettes appears
to have a biological basis. Nicotine can bypass aspects of the brain’s reward system that
is generally underactive during depression and temporarily increase dopamine and other
neurotransmitters associated with positive mood (Leventhal et al., 2014; Schlaepfer et al.,
13

2008; Wise et al., 2008). This underactive reward system leads non-drug reinforcers to be
less stimulating (e.g., they do not stimulate the release of as much dopamine) and less
reinforcing compared to nicotine (Nutt et al., 2007; Leventhal et al., 2014). In sum, a
smoker with depressive symptoms is more likely to choose to continue smoking because
they find smoking more immediately reinforcing and gain more reinforcing value from
smoking compared to other non-drug activities that involve relatively delayed
reinforcement.
Smoking can be viewed as a maladaptive strategy to cope with stress that is
reinforced over time (Chase et al., 2018). As mentioned earlier, smoking temporarily
increases dopaminergic activity in the brain’s reward system and activates the HPA axis,
which modulates negative affect and depressive systems (Cosci et al., 2014). This
temporary “boost” in mood may be especially salient to those with few alternative nondrug reinforcers (e.g., those with depressive symptoms) and continues to reinforce the
cycle of smoking and stress (Cosci et al., 2014; Piper et al., 2013). Despite this temporary
increase in positive mood, smoking is associated with decreases in serotonin and 5hydroxindolactectic acid (5-HIAA) which are associated with worsening depressive
symptoms and negative mood over time (Cosci et al., 2014; Martinez-Ortega et al., 2017;
Piper et al., 2013). In other words, people with current or a history of depressive
symptoms may overvalue cigarettes, find them more reinforcing than alternative nondrug reinforcers, and be less likely to engage in non-smoking coping behavior when
under stress.
Beyond these broad theories of reinforcement, which apply to both males and
females, women may be at higher risk for overvaluing cigarettes due to the impact of
14

ovarian hormones, which fluctuate during the perinatal period and impact the
aforementioned brain reward system. Ovarian hormones have been examined as
mechanisms for maintaining smoking in women and found to be significant contributors
to the overvaluation of cigarettes, particularly under stress (Farris et al., 2018; Perkins et
al., 2013; Weinberger & McKee, 2012; Weinberger et al., 2015). Higher levels of
estrogen, such as those observed during pregnancy, are associated with the increased
reinforcing value of smoking (Lynch & Sofuoglu, 2010). Further, low levels of
progesterone and estrogen, such as those observed immediately following delivery, have
been associated with emotional dysregulation, which for women who utilize smoking as a
coping strategy, increases the likelihood of maintaining smoking as well as postpartum
relapse (Nillni et al., 2015). The connection between emotional dysregulation, hormones,
and the increased reinforcing value of cigarettes may exacerbate depressive symptoms
and maintain smoking, particularly during times of intense hormonal fluctuation and
stress (i.e., the perinatal period).
Screening and Treatment of Depressive Symptoms in Pregnancy
For perinatal women, the combination of deleterious effects of smoking and
depressive symptomatology, their bidirectional relationship, and overlapping risk factors
highlight the need for interventions which impact both smoking and psychological
symptoms during this stressful time period. A recent review by Mathew and colleagues
(2017) recommended that smoking cessation interventions should utilize behavioral
strategies to target the overvaluation of cigarettes found among smokers with depressive
symptoms. We first briefly review treatment of perinatal depressive symptoms before
moving on to discussing perinatal smoking cessation treatment.
15

As the pervasive negative impacts of perinatal depressive symptoms have been
elucidated, there has been a call for early screening and increased intervention. The U.S.
Preventive Services Task Force issued a recommendation in 2016 encouraging screening
for psychological symptoms during pregnancy and in the postpartum (O’Connor et al.,
2016). The American College of Obstetricians and Gynecologists (ACOG) recommends
screening at least once during perinatal and the American Academy of Pediatrics
recommends continued screening through 4-months postpartum (Committee on Obstetric
Practice, 2015; Earls, 2010). The Edinburgh Postnatal Depression Scale (EPDS) is the
most widely used depression-screening tool for perinatal symptoms and is recommended
by ACOG (Howard et al., 2017; Milgrom & Gemmill, 2014). It was developed to screen
for perinatal depressive symptoms and has been validated across antepartum, postpartum,
and cross-cultural samples (Cox et al., 1987; Kozinszky & Dudas, 2015; McCallHosenfeld et al., 2016; Rubertsson et al., 2011; Ruyak et al., 2018). While there is some
debate about the optimal cut-off score for sensitivity and specificity, women receiving a
score of ten or higher generally endorse a significant amount of depressive
symptomatology, although they may fail to meet formal diagnostic criteria for major
depressive disorder (Eberhard-Gran et al., 2014). While these women may exhibit
subclinical ranges of depression, they may still benefit from intervention.
Regarding treatment for depressive symptoms, many pregnant and postpartum
women express preference for psychotherapy over pharmacotherapy (Battle et al., 2013).
While data are still largely inconclusive about the potential impact of antidepressants on
fetal development and birth outcomes, many women still worry about potential adverse
effects. One review found that there is no increased risk to fetal development associated
16

with antidepressants (Byatt et al., 2013); however, a review by the American Psychiatric
Association (APA) and ACOG concluded that there was neither evidence for nor against
the safety of antidepressants during pregnancy (Yonkers et al., 2009). Other studies have
found some negative associations with continuing antidepressant use during pregnancy
(e.g., poor fetal growth; Zhao et al., 2018). Another recent review did not find differences
when examining low birth weight and related birth outcomes between women receiving
antidepressants and those who were untreated, although the authors did caution that more
studies are needed for a more definitive answer (Mitchell & Goodman, 2018). While
research is ongoing, the current consensus among most treatment providers is that the
potential risks associated with antidepressants should be compared against the potential
risk of continued depressive symptoms for mother and offspring (Becker et al., 2016).
Alternatively, the use of psychotherapy, particularly cognitive behavioral therapy and
interpersonal therapy modalities, can be effective for treating depressive symptoms in this
population (Battle et al., 2013; Miniati et al., 2014; Sockol et al., 2011; Stuart & Koleva,
2014).
Smoking Cessation Treatment in Pregnancy
Similar to hesitations about the use of pharmacotherapy to treat depressive
symptoms, providers and perinatal women are often hesitant to utilize nicotine
replacement therapy for smoking cessation for fear of negative effects on fetal growth or
birth outcomes (Wilson et al., 2018). A recent meta-analysis did not find psychotherapy
alone to be effective for smoking cessation among perinatal women but did find that
contingency management (the use of financial incentives for smoking abstinence) was
efficacious (Wilson et al., 2018).
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Contingency management is a behavioral economic intervention that utilizes
systematic reinforcement of objectively verifiable changes in target behaviors (e.g.,
smoking abstinence) in an attempt to promote behavior change (e.g., continued smoking
during pregnancy; e.g., Bigelow & Silverman, 1999; Higgins, 1997; Roll & Higgins,
2000). This intervention is efficacious across various substance use disorders and
populations, including some highly treatment-resistant groups such as those with
comorbid psychological disorders and perinatal women (Davis et al., 2016; Drake et al.,
2008; Higgins et al., 1994a, b; Higgins et al., 2004; Higgins et al., 2012; Higgins &
Solomon, 2016; Sigmon & Higgins, 2006; Silverman et al., 1996; Stitzer et al., 1993;
Weinstock et al., 2007).
Contingency management targeting smoking cessation typically provides
financial incentives in the form of vouchers exchangeable for goods or services,
contingent on biochemically verified abstinence from smoking. When used in perinatal
populations, this treatment has been found to not only impact smoking rates, but also
leads to improvements in birth outcomes (e.g., birth weight) and increases in
breastfeeding duration (Higgins et al., 2010a; 2010b). Financial incentives targeting
substance use have been reported to reduce psychological symptomatology in both nonpregnant adults and women at risk for perinatal depression (Higgins et al., 1994a; Lopez
et al., 2015; Petry et al., 2013; Zvorsky et al., 2017). Regarding the perinatal population,
Lopez and colleagues (2015) examined whether financial incentives were efficacious for
smoking cessation among pregnant and postpartum women who were at increased risk
for depression (depression-prone; Dep+) compared to lower risk (depression-negative;
Dep-) women. The efficacy of the incentives intervention for smoking cessation was
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comparable among Dep+ and Dep- women; moreover, the Dep+ women who received
the incentives intervention also experienced a significant reduction in postpartum
depressive symptoms while comparable women in the control condition did not (Lopez et
al., 2015).
The Lopez et al., (2015) findings were subsequently extended by demonstrating
that the incentives intervention impacted a broad array of psychological symptoms
among Dep+ women as measured by the Brief Symptom Inventory (BSI; Zvorsky et al.,
2017). That is, Dep+ women who received abstinence-contingent incentives saw greater
reductions on BSI subscale scores measuring global distress, depression, anxiety, phobic
anxiety, interpersonal sensitivity, paranoid ideation, psychoticism, somatization, and
obsessive-compulsive than Dep+ women in the control condition who received incentives
of comparable value but provided independent of smoking status (i.e., non-contingent
incentives controls). These treatment effects were partially mediated by smoking
abstinence (Zvorsky et al., 2017), with this difference between incentives delivered
contingent on smoking cessation versus non-contingently suggesting that targeting a
goal-directed behavior may have been key to their impact on psychological symptoms
(Zvorsky et al., 2017). While smoking status was demonstrated to partially mediate these
treatment effects across several BSI subscales, smoking status did not fully account for
the reduction in psychological symptoms. That is, effects on symptoms among Dep+
women treated in the incentives condition also extended to women who did not achieve
smoking abstinence. This raised the possibility that the observed treatment effects may be
best explained within a larger behavioral framework (e.g., Mathew et al., 2017; Secades-
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Villa et al., 2017) or, of course, the possibility that they were attributable to extraneous or
confounding factors.
Regarding the possibility that financial incentives for smoking cessation may have
effects on depression through mechanisms other than smoking status, incentive
interventions provide repeated opportunities to receive positive reinforcement for goaldirected behavior while attempting to inhibit the targeted behavior (Kanter et al., 2010).
Overtime, repeated engagement with the opportunity to earn reinforcement may increase
goal-directed behavior, even if the participant is not sufficiently able to achieve sustained
abstinence. The potential to earn these reinforcers may also attenuate the overvaluation of
cigarettes and decrease the relative reinforcing value of smoking. Taking a biological
perspective, financial incentives may also impact the brain’s reward system similarly to
substance use itself and override systems which are suppressed due to depressive
symptoms or prolonged smoking (Aston-Jones & Cohen, 2005; Garavan & Hester, 2007;
Knutson et al., 2001; Higgins et al., 2012). In sum, the use of financial incentives directly
targets the reinforcer pathology (i.e., the overvaluation of the reinforcing value of
cigarettes) exhibited by smokers with depressive symptoms.
Importantly, this potential effect on reinforcer pathology can be assessed using the
Cigarette Purchase Task (CPT), which is included in the present study. The CPT is a
behavioral-economic task used to investigate the reinforcing value of smoking by having
individuals estimate the number of cigarettes they would purchase in a 24-hour period
across an increasing range of monetary prices (Bickel et al., 2010; Jacobs & Bickel,
1999; Vuchinch & Heather, 2003). The CPT has been validated as a safe, ethical, and
cost- and time-effective measure of demand for substances in vulnerable populations
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(e.g., pregnant women; Jacobs & Bickel, 1999; Bickel & Madden, 1999a, 1999b; Higgins
et al., 2017). Utilizing the CPT in the present study provides an opportunity to elucidate
the impact of financial incentives on the reinforcing value of cigarettes in a population
that is trying to quit smoking. Further, there is some preliminary evidence that demand
for cigarettes as measured by the CPT is decreased through the use of financial incentives
and that this decrease in the reinforcing value of cigarettes is associated with decreased
smoking (Weidberg et al., 2018).
In sum, financial incentives for smoking cessation may lead to a reduction in
depressive symptoms among women at increased risk for perinatal depression by
decreasing smoking and through behavioral strategies that reinforce goal-directed
behavior. This interaction with potential earnings may reduce the overvaluation of the
reinforcing value of cigarettes over time by increasing the associated costs of smoking.
This shift in overvaluation may be particularly important for women at risk for depressive
symptoms.
The Current Study
There are two primary aims to this prospective randomized, controlled smoking
cessation trial examining the efficacy of financial incentives within pregnant and
postpartum women. First, the study aims to replicate prior research examining the
treatment effects of financial incentives on smoking status among women at heightened
risk for developing perinatal depression (i.e., depression-prone women). Lopez et al.
(2015) demonstrated that Dep+ women who received abstinence-contingent financial
incentives were able to quit at comparable rates to Dep- women who received the same
treatment and at significantly greater rates than Dep + and Dep - women in the control
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condition. This primary aim will be addressed by comparing perinatal abstinence rates
among Dep+ and Dep- women randomized to Best Practices alone (brief counseling with
a referral to a pregnancy-specific quit line) or Best Practices combined with abstinencecontingent financial incentives. A secondary aim that fits within this primary aim on
cessation is to examine whether baseline reinforcing value of cigarettes as measured by
the CPT predicts perinatal abstinence rates after accounting for baseline smoking rates,
and treatment condition. As discussed above, the literature suggests that those with
depressive symptoms may overvalue cigarettes and this makes it more difficult to quit
smoking. This secondary aim will be examined by including the CPT indices in a model
with depression risk status and treatment condition predicting abstinence.
The second primary aim of this study is to examine the impact of financial
incentives on the perinatal course of depressive symptoms in Dep+ women. This primary
aim will be addressed by examining whether Dep+ women in the Incentives condition
experience reductions in depressive symptoms using the BDI as in the Lopez et al. study
as well as the Edinburgh Postnatal Depression Scale (EPDS; Cox et al., 1987), which is
designed for the explicit purpose of assessing depression symptoms independent of
pregnancy-related somatic symptoms. Any significant treatment effects on depressive
symptoms will be examined for potential mediators (i.e., smoking status, the reinforcing
value of cigarettes, perceived social support, and confidence in quitting).
A related secondary aim of this study is to examine the relationship of smoking
and depressive symptoms in the opposite direction by examining whether ongoing
smoking impacts depressive symptoms independent of treatment condition. As discussed
above, the literature suggests that those who continue to smoke will have more severe
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symptomology. Lopez et al. (2015) demonstrated that Dep+ abstainers had lower BDI
scores than Dep+ smokers who continued smoking and Zvorsky et al. (2017)
demonstrated that the treatment effect on psychological symptoms was partially mediated
by smoking status. This secondary aim will be explored by examining the impact of
smoking status on depressive symptoms among Dep+ and Dep- women.
A third and final secondary aim of this study is to examine potential differences
between the BDI and EPDS in assessing perinatal depressive symptoms in this
socioeconomically disadvantaged population of cigarette smokers. This secondary aim
will be explored by first examining correlations of items that capture similar constructs
between both instruments. Next, the likelihood of a participant being categorized as Dep+
will be examined using cut points for each measure. Differences in responses on both the
BDI and EPDS for participants categorized as Dep+ by each measure will be examined to
elucidate which symptoms on each instrument are capturing facets of perinatal
depression.
Based on prior studies and theory outlined above, we hypothesize that women
who are at heightened risk for perinatal depression and who are randomized into the Best
Practices + Incentives condition will achieve greater rates of abstinence than those in
Dep+ women in the Best Practices alone condition in a manner that is comparable to
effects among Dep- women. Addressing the related secondary aim, we hypothesize that
lower baseline reinforcing value of cigarettes will independently predict perinatal
smoking abstinence rates.
Further, we hypothesize that Dep+ women assigned to the Best Practices plus
Incentives condition will experience significantly greater reductions in depressive
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symptoms than Dep+ women assigned to the Best Practices only condition. If treatment
significantly reduces depressive symptoms, we posit that these treatment effects will act
through mechanisms associated with the reinforcing value of cigarettes, perceived sense
of social support, and confidence in quitting smoking. We hypothesize that changes in
smoking status, demand, perceived social support, and confidence in quitting will
partially mediate treatment effects. Lastly, we hypothesize that women who continue
smoking during treatment will have greater depressive symptoms than abstainers
independent of treatment condition.
Methods
Participants
Participants were 169 pregnant women enrolled in a randomized, controlled
smoking cessation trial examining the efficacy and cost effectiveness of financial
incentives. The local institutional review board approved this trial and all participants
provided written informed consent. Women were recruited from obstetric practices and
the Women, Infants, and Children (WIC) program in Burlington, VT and surrounding
areas. All patients at participating practices and WIC offices filled out screening
questionnaires and were invited to participate in an intake assessment if they indicated
interest in doing so. Inclusion criteria included biochemically-verified smoking within the
past seven days, residing within the study clinic’s designated counties with no plans to
leave the area in the next year, being at least 18 years of age, and English speaking.
Exclusion criteria included taking anti-psychotic or psychomotor-stimulant medications,
receiving maintenance medication for opioid use disorder, incarceration, pregnancy
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beyond 25 weeks gestational age, and residing with a participant currently enrolled in the
study.
Treatment Conditions
After eligibility was determined and informed consent obtained, participants were
randomly assigned to one of two conditions: (a) a Best Practices control condition
wherein participants received brief counseling by clinic staff using the 5 A’s (Fiore et al.,
2008) and a referral to the Vermont pregnancy-specific quit-line or (b) the same Best
Practices intervention plus Financial Incentives (Best Practices + Incentives) in the form
of vouchers exchangeable for retail items contingent on biochemically-verified smoking
abstinence. The voucher schedule for this on-going trial resembles that of previous trials
(e.g., Higgins et al., 2012). Briefly, participants in the Best Practices + Incentives
condition had the opportunity to earn vouchers for biochemically-verified smoking
abstinence using breath carbon monoxide samples ≤ 6ppm in the first week followed by
urinary cotinine levels <80 ng/ mL using onsite Enzyme Immunoassay Testing through
12-weeks postpartum. Participants smoking less than 10 cigarettes per day had the
opportunity to earn up to $1,180 throughout the trial. Participants smoking 10 or more
cigarettes per day had the opportunity to earn a maximum of $2,360 in vouchers as they
have greater difficulty achieving abstinence (e.g., Higgins et al., 2012).
Assessments
All participants completed a total of nine assessments, three antepartum and six
postpartum. The antepartum assessment schedule included an initial intake visit (<25
weeks gestational age), an early pregnancy assessment (1 month following intake), and a
late pregnancy assessment (≥ 28 weeks gestational age). Postpartum assessments
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occurred 2-, 4-, 8-, 12-, 24, and 50- weeks after delivery. At study intake, participants
completed questionnaires examining sociodemographic characteristics, smoking status
and history, and two questionnaires examining psychological symptomatology: the Beck
Depression Inventory-1A (BDI; Beck, Steer, & Brown, 1996) and the Edinburgh
Postnatal Depression Scale (EPDS; Cox et al., 1987). They also responded to questions
about confidence in ability to quit (or stay quit) and perceived social support for quitting
smoking. Finally, participants also completed the Cigarette Purchase Task (CPT; Jacobs
& Bickel, 1999) which is a behavioral economic task that models the reinforcing value of
cigarettes by asking participants to estimate hypothetically how many cigarettes they
would purchase in a 24-hour period if they were available across a range of different
prices. These measures were completed at each of the subsequent assessments, except for
demographics.
Psychological Symptoms
Psychological symptoms were measured using the BDI and EPDS to determine
which participants are at heightened risk for perinatal depression. Treatment effects on
psychological symptoms were examined utilizing the BDI to replicate previous findings
and the EPDS, a measure developed specifically for use in the perinatal The EPDS was
included in the present study with the goal of eliminating potential variance attributable
to mischaracterizing symptoms of pregnancy for depressive symptoms and associated
potential erroneous inferences regarding treatment effects.
The BDI (version IA) is a 21-item self-report questionnaire focused explicitly on
depressive symptoms. Each item includes four statements assessing intensity of
symptoms ranging from mild to severe during the past two weeks (Beck et al., 1996). The
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BDI timeframe was altered from the past two weeks to the past week to match the EPDS.
The EPDS is a 10-item self-report questionnaire that was developed to assess depressive
symptoms among perinatal women that has been validated in pregnant samples (Cox et
al., 1987; Kozinszky & Dudas, 2015). Each item contains four statements examining
intensity of symptoms ranging from not present to severe over the past week.
Importantly, this measure removes somatic symptoms attributable to pregnancy and the
postpartum period that are often included in traditional measures for psychological
symptoms (i.e., weight change and appetite change; Cox et al., 1987).
To keep criteria in the present study aligned with those used in the Lopez et al.
(2015) study, the same depression history and BDI cut points were utilized as qualifiers
for depression risk status. Participants were categorized as at heightened risk for
depression (depression-prone; Dep+) or at lower risk for depression (depression-negative;
Dep-) based on self-reported history of depression at intake and a BDI intake score above
a validated cut point. Self-reported history of depression was assessed by the question,
“Have you ever had any of the following feelings nearly every day for two or more weeks
at a time: down, depressed, hopeless, little interest or pleasure in doing things?”.
Participants could be categorized as Dep+ if they endorsed either (a) a self-reported
history of depression and/or (b) a BDI score at or above 17, the cut point for mild
depressive symptoms. Participants were categorized as Dep- if they did not report a
history of depression and did not have a BDI score at or above 17. Comparable analyses
were also conducted utilizing the same history criteria and an EPDS cut point of 10.
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Potential Mediators
The reinforcing value of cigarettes was measured using the CPT (Jacobs & Bickel,
1999). Hypothetical purchase tasks are increasingly used in substance use research to
discern individual differences in risk for and markers of problematic use (e.g., dependence,
comorbid psychiatric symptoms) in addition to response to clinical or regulatory
interventions (Roma et al., 2017; Zvorsky et al., under review).
Five indices can be derived from the CPT that elucidate different aspects of the
reinforcing value of cigarettes: estimated number of cigarettes smoked per day if cigarettes
were free (Intensity); how much participants are willing to spend daily on smoking (Omax);
the price at which smoking rate begins to decrease proportionate to increases in price
(Pmax); the price at which participants indicate they would cease smoking rather than incur
the cost (Breakpoint); and overall sensitivity to increases in price (Elasticity).
Perceived social support and confidence in ability to quit were measured using five
5-point Likert scale questions. The Likert scale includes responses of ‘not at all’ (1), ‘a
little’ (2), ‘some’ (3), a lot (4), and ‘I don’t know’ (5). One question targeted perceived
social support, “If you decided to quit smoking, how much support or understanding do
you think you would get from family, friends, and coworkers?”. Four questions assessed
confidence in ability quit, “If you decided to quit smoking during the next month, how
confident are you that you could do it?; How confident are you that you could handle stress
or anxiety without smoking?; How confident are you that you can handle feeling sad or
depressed without smoking?; How confident are you that you can handle being around
other people who are smoking without smoking?”.
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Smoking status was determined using self-report responses (“Have you smoked a
cigarette, even a puff, in the past 7 days?”) and biochemical verification utilizing breath
carbon monoxide levels ≤ 6 ppm in the first week only and urinary cotinine levels <80
ng/mL throughout the study using onsite Enzyme Immunoassay testing. These levels have
been established as appropriate cut points for assessing smoking status in pregnant and
postpartum women (Higgins et al., 2007).
Statistical Methods
Data were analyzed for all participants (N=169). Baseline demographic and
smoking characteristics were compared between treatment conditions (Best Practices
only vs. Best Practices + Incentives) and depression risk status (Dep+ vs. Dep-) using
chi-square tests or t-tests for categorical variables and variance-tests for continuous
variables. Stress ratings significantly differed between treatment conditions at baseline
and were included in models examining treatment effects.
To attempt to confirm the observed effect of treatment condition on smoking
status and replicate the findings of Lopez et al., (2015) that Dep+ and Dep- participants
treated with Incentives achieved greater abstinence than their counterparts in the Best
Practices only control condition, a repeated measures analysis for dichotomous dependent
data based on generalized estimating equations with a logistic link function was utilized
across all nine assessments. Main effects and two-way and three-way interactions
between treatment condition, risk status, and time were examined. Baseline self-reported
stress levels over the past week differed significantly by treatment condition and thus
were also included in the model as a covariate.
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T-tests were utilized to examine differences between depression risk status (Dep+
vs. Dep-) on CPT indices. CPT indices were log transformed and means and 95%
confidence intervals were back-calculated to the original scale. To understand whether
the reinforcing value of cigarettes impacts abstinence achieved during pregnancy and
postpartum, a repeated measures logistic regression was utilized to examine whether
baseline CPT indices predicted 7-day point prevalence smoking abstinence across all
study assessments. Treatment condition, depression risk status, and baseline cigarettes
per day (a predictor of ability to quit correlated with CPT indices; e.g., Kurti et al., 2016;
White et al., 2014), along with two- and three-way interactions of CPT indices,
depression status, and time, were included in the model.
To replicate the prior findings by Lopez et al. (2015) that financial incentives
significantly reduced BDI scores across the perinatal, a repeated measures analysis based
on a linear mixed model was utilized across all nine assessments. Main effects and
interactions between treatment condition, risk status, and time were examined. Baseline
self-reported stress level over the past week significantly differed by treatment condition
and was included in the model as a covariate. A lack of significant interaction effects
between treatment condition, depression risk status, and time prevented further
exploration of possible mediators of treatment effects.
A similar analysis was completed to examine the effect of treatment condition on
EPDS scores using a repeated measures analysis of covariance across all nine
assessments. Main effects and interactions between treatment condition, risk status, and
time were examined with baseline self-reported stress level over the past week included
as a covariate. A lack of significant interaction effects between treatment condition,
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depression risk status, and time prevented further exploration of mediators of treatment
effects.
To ensure that potential treatment effects on depressive symptoms were not
artifact of using a non-perinatal specific depression screener (i.e., BDI), we also
investigated treatment effects on depression scores using baseline EPDS rather than BDI
scores to categorize women as depression-prone (Dep+E) or depression-negative (DepE). The EPDS cutoff for depression risk status was 10 or above. Endorsing a history of
depressive symptoms at baseline continued to be grounds for being categorized as
depression-prone in this analysis. A repeated measures analysis of covariance was
utilized across all nine assessments using the EPDS depression risk status categories
examining BDI and EPDS scores.
A 2-way ANOVA was conducted to examine whether smoking status impacted
depressive symptom scores on both the BDI and EPDS. Depression risk status, smoking
status, and the interaction of the two were included in the models.
To examine whether differences between the BDI and EPDS impacted likelihood
of being categorized as Dep+, a cross-tabs analysis was conducted to elucidate rates of
identifying participants for potential depression.
All analyses were performed using SAS Version 9 statistical software (SAS
Institute, Cary NC). Missing data was handled utilized maximum likelihood estimation.
Statistical significance was set at alpha < .05.
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Results
Participant Characteristics
Participants were young (26.0  5.2), socioeconomically disadvantaged women.
The majority completed 12 or fewer years of education (78%), were unmarried (82%),
and without private insurance (72%, e.g., receiving Medicaid; Table 1). Among the 169
participants, 81 were randomized to the Best Practices + Incentives condition and 88 to
the Best Practices only condition. Significant baseline differences were noted for stress
ratings, with higher ratings in the Best Practices compared to the Best Practices +
Incentives condition (6.3  2.2 vs 5.0  2.5). Significant differences were also observed
for BDI scores at baseline with the Best Practices only condition having significantly
higher scores than the Best Practices + Incentives condition (12.8  8.6 vs. 10.0  7.4).
No other significant baseline differences between treatment conditions were observed.
Depression risk status was calculated for 167 of the 169 participants due to
missing data for two participants. Among the 167 participants with a baseline BDI score,
91 (54%) were categorized as depression-prone (Dep+) and 76 (46%) as depressionnegative (Dep-). Dep+ women had significantly lower confidence about handling stress
and anxiety without smoking compared to Dep- women (2.14  0.10 vs. 2.74 + 0.12, p
<.001). Dep+ women also had significantly lower confidence about handling being sad or
depressed without smoking compared to Dep- women (2.66  0.11 vs. 3.43  0.10, p
<.001). No other significant differences in confidence to avoid smoking were observed.
No significant differences were observed for perceived social support by depression risk
status (p>.05). As expected, significant baseline differences were observed with Dep+
having higher BDI scores (15.8  8.3 vs. 6.3  3.7), a greater percentage endorsing a
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history of depression (88% vs. 0%; Table 1), and greater stress ratings (6.4  2.2 vs. 4.7 
2.4). The only significant difference in smoking characteristics was observed for nicotine
withdrawal scores with Dep+ women endorsing more baseline withdrawal symptoms
than Dep- women (1.8  0.7 vs. 1.1  0.6).
No significant baseline CPT differences were observed by depression status.
Dep+ women did not endorse higher Intensity (M=14.26, 95% CI [12.33-16.50])
compared to Dep- women (M=13.90, 95% CI (12.08-16.00]) nor higher Omax (M=7.47,
95% CI [6.04-9.10]) vs. M=6.69, 95% CI [5.52-8.10]), Pmax (M=0.99, 95% CI [0.75-1.31]
vs. M=0.87, 95% CI [0.66-1.15]), Breakpoint (M=1.56, 95% CI [1.20-2.04] vs. M=1.30,
95% CI [1.00-1.70]), nor lower Elasticity (M=0.01, 95% CI [0.01-0.02] vs. M=0.02, 95%
CI [0.01-0.02]).
Treatment Effects on Smoking Status
The Best Practices + Incentives intervention increased 7-day point prevalence
abstinence rates through 12-weeks postpartum (the duration of the intervention; Figure
1). There was a main effect of treatment condition (X2[1] = 7.52, p < .01), time (X2[7] =
35.28, p < .0001), and interaction of treatment and time (X2[7] = 24.73, p < .001). There
were no significant interactions of treatment condition and depression status (X2[1] =
2.37, p = .12), depression status and time (X2[7] = 3.53, p = .83), or treatment condition,
depression status, and time (X2[7] = 6.43, p = .49). In sum, depression risk status had no
significant influence on treatment effects.
Baseline CPT Intensity ratings significantly predicted smoking abstinence at all
time points except for the 50-weeks postpartum assessment after controlling for treatment
condition, depression status, and baseline cigarettes per day (B= -0.07, 95% CI [ -0.11 - 33

0.02, p < .01, Tables 2 and 3). No other CPT indices predicted smoking abstinence (p >
.05).
Treatment Effects on Depressive Symptoms
There was no significant main effect of treatment condition on depressive
symptoms as assessed by the BDI ( F[1,163] = 0.05, p = .83) nor were there significant
interactions of treatment condition and depression status (F[1,164]= 0.72, p = .40),
treatment and time (F[8,1055] = 1.01, p > .05) or treatment, depression status, and time
(F[8,1054] = 0.99, p = .44; Figure 2). There was a significant main effect of depression

risk status with Dep+ women reporting higher scores compared to Dep- women (F [1,
164] = 24.95, p < .0001); Figure 3). There was a significant two-way interaction between
depression status and time (F [8, 1054] = 3.18, p = .001) with significant decreases in
BDI scores over time among the Dep+ but not Dep- women, independent of treatment
condition.
Treatment effects on EPDS scores (Figure 4) paralleled those outlined above for
BDI scores with no significant main effect for treatment condition (F[1,166] = 1.15, p =
.28) nor interactions of treatment condition and depression status (F[1,166] = 0.98, p =
.32), treatment and time (F[8,1059] = 1.61, p = .12) or treatment, depression status, and
time (F[8,1059] = 1.02, p = .42). Also paralleling what was seen with BDI scores, there
was a significant main effect of depression risk status (F [1, 166] = 57.06, p < .0001) and
significant differences between the depression status groups at all assessments (Figure 5).
There was a significant two-way interaction between depression status and time (F [8.
1059] = 3.54, p = .001), with scores decreasing over time among the Dep+ but not the
Dep- women regardless of treatment condition.
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Examining depressive symptoms utilizing depression risk status categorized by
baseline EPDS scores ≥ 10 and self-reported history of depression yielded results
consistent with those mentioned above. There was no significant main effect for
treatment condition on BDI scores during treatment and follow-up (F [1,166] = 0.01, p =
.94), nor significant interactions of treatment condition and depression status (F [1,166] =
0.27, p = .61) or treatment condition, depression status, and time (F [8,1068] = 0.66, p =
.31; Figure 6). There was a significant main effect of depression risk status (F [1, 166] =
12.18, p < .0001) and a significant two-way interaction between depression status and
time (F [8. 1068] = 5.48, p < .001) with scores decreasing over time among the Dep+ but
not the Dep- women.
Similarly, there was no significant main effect for treatment condition on EPDS
scores during treatment and follow-up (F [1,164] = 0.01, p = .97), nor significant
interactions of treatment condition and depression status (F [1,165] = 0.38, p = .54) or
treatment condition, depression status, and time (F [8,1060] = 1.03, p = .41; Figure 7).
There was a significant main effect of depression risk status (F [1, 164] = 35.1, p < .0001)
and a significant two-way interaction between depression risk status and time (F [8,
1060] = 3.57, p < .001) with EPDS scores decreasing over time among the Dep+ but not
the Dep- women.

Smoking Status Effects on Depressive Symptoms
As mentioned above, depression risk status did not significantly impact smoking
status in this study. Dep+ women were not less likely to quit compared to Dep- women.
When examining this relationship in the opposite direction, smoking status did not
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significantly impact BDI scores at any assessment (ps > .05). BDI scores did not
significantly differ between smokers and abstainers at any time point, even when
examining Dep+ women only. As expected, BDI scores differed between depression risk
status groups at all time points, with Dep+ women reporting higher scores compared to
Dep- women (Table 4). No main effects of smoking status or interaction effects between
smoking status and depression risk status were observed (Table 4). In sum, smoking
status was not significantly associated with BDI scores.
When examining EPDS scores, a similar pattern emerged. EPDS scores did not
significantly differ between smokers and abstainers at any time point, even when
examining Dep+ women only, except for one early pregnancy assessment (Table 5). At
this one time point, smokers had higher EPDS scores than abstainers. As expected, EPDS
scores differed between depression risk status groups at all time points, with Dep+
women reporting higher scores compared to Dep- women (Table 5). No main effects for
smoking status or interaction effects between smoking status and depression risk status
were observed (Table 5). In sum, smoking status was not significantly associated with
EPDS scores.
Comparison of BDI and EPDS Screeners for Perinatal Depression
When examining cross-tabs on participants categorized as having a greater risk of
depression by BDI and EPDS baseline cut point criteria, differences between the two
instruments were observed. Overall, 87 participants were considered as depressionnegative by both instruments and 43 participants were identified as depression-prone by
both instruments. The BDI identified a total of 89 participants as Dep+, two of whom
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were not identified by the EPDS cut point. The EPDS identified 78 participants as
depression-prone (Dep+E), 35 of whom were not identified by the BDI.
Exploring various cut points that matched for both measures continued to yield
differences, although as the value of the cut points increased, the discrepancies between
the two measures was reduced. When the cut point for both measures was 10, the number
of additional participants identified by the EPDS was reduced to 13. When the cut point
was 17 for both instruments, the number of additional participants identified by the EPDS
was reduced further to 3. Finally, when the cut point was 21 for both instruments, no
differences were observed between women identified as depression-prone by the BDI and
EPDS.
Discussion
The present study had two primary aims: examine whether women at risk for
perinatal depression achieve greater smoking abstinence when treated with financial
incentives compared to a control intervention and whether this intervention also reduces
perinatal depressive symptoms more than the control intervention. Both treatment effects
were reported in secondary analyses of previously collected data (Lopez et al., 2015;
Zvorsky et al., 2017). The present study provided an opportunity to systematically
replicate those important findings in a prospective randomized controlled clinical trial
using a perinatal-specific instrument (i.e., EPDS) to assess depressive symptoms.
Treatment effects on smoking cessation were confirmed in the present study.
Dep+ women achieved abstinence at rates significantly greater than their Dep+
counterparts randomly assigned to treatment without financial incentives. The differences
in abstinence rates between treatment conditions for the Dep+ women were comparable
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to the differences observed between treatment conditions for the Dep- women. These
results demonstrate that financial incentives for smoking cessation are effective in a
perinatal population and, specifically, are effective among women with elevated
depressive symptoms.
This study did not replicate prior findings by Lopez et al. (2015) and Zvorsky et
al. (2017) that incentives-based smoking cessation interventions differentially decrease
depressive and other psychological symptoms in Dep+ perinatal women compared to the
control treatment. Important to clarify is that symptoms among the Dep+ women
assigned to the incentives condition did decrease significantly during the course of
treatment and follow-up as in the prior studies, but in the present study, comparable
reductions were also observed in the control treatment. In the prior study depressive
symptoms remained elevated throughout treatment and follow-up among women
assigned to the control treatment condition. This lack of significant treatment effect may
be due to several reasons. First, different control conditions were utilized in the present
and prior studies. In the Lopez et al. (2015) and Zvorsky et al. (2017) studies, a
noncontingent voucher control condition was utilized wherein participants received
vouchers of comparable value to those in the abstinence-incentive condition but provided
independent of smoking status. As noted above, depressive symptoms remained elevated
throughout the intervention in the non-contingent incentives control condition whereas
they decreased in both treatment conditions in the present study. Receiving incentives
non-contingently may have somehow highlighted participants’ inability to quit or perhaps
amplified feelings of guilt, shame, or frustration, leading to depressive symptoms
remaining elevated. Non-contingent aversive events have been shown to increase
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negative symptoms like anxiety and noncontingent failure has been linked to increased
depressive symptoms and a sense of helplessness (Griffith, 1977). It is not clear why noncontingent positive incentives would have a similar effect, but it is clear that they are not
going to increase goal-directed behavior in the same manner as contingent incentives.
An alternative and more likely explanation that merits consideration is that
perinatal depressive symptoms may have decreased in both treatment conditions in this
trial due to increased awareness, screening, and intervention for perinatal mood disorders
in routine obstetrical care. A recent review reported that there have been increases in the
integration of mental health screening in obstetric care during the perinatal period and a
movement toward integrating treatment or referral for positive screening (O’Hara &
McCabe, 2013). Specifically, as of 2015, 13 states (including Vermont) have enacted
policies directly targeting increased awareness, screening, and intervention for perinatal
mental health (Rowan, Duckett, & Wang, 2015). Additionally, there is a nationwide
effort to address perinatal mental health as the American College of Obstetricians and
Gynecologists has released and continues to update recommendations for screening and
interventions within obstetric and gynecological practices specifically targeting mental
health during this critical time period (ACOG, 2015; ACOG, 2018). This shift and
continued effort towards integration of mental health in obstetric care may be impacting
the depressive symptoms in this sample of perinatal women. While this is of great benefit
for the population at large, it may obviate any additional benefit that the use of incentives
for smoking cessation may have on perinatal psychological symptoms.
Another critical difference between the present and prior studies is the lack of a
significant association between smoking status and depressive symptoms and a lack of
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evidence that CPT ratings of the relative reinforcing value of cigarettes differed by
depression status. In Lopez et al. (2015), smoking status had a significant mediating
effect on BDI scores and in Zvorsky et al., (2017) smoking status partially mediated
treatment effects on a broader array of psychological symptoms. The literature has long
associated smoking status with increased depressive symptoms and commented on the
bidirectional nature of this relationship (e.g., Fluharty et al., 2017; Leventhal &
Zvolensky, 2015; Morozova et al., 2015). Recent literature has also noted increased
demand for smoking among smokers with depression compared to those without (e.g.,
Leventhal et al., 2014). Those differences were not observed in the present study. We
saw no significant associations between smoking status and depressive symptoms
assessed with the BDI or EPDS nor greater demand for smoking among the Dep+ women
compared to the Dep- women on the CPT. These are unexpected results given that
average BDI scores at intake were similar to those observed in the prior studies, so this
lack of difference cannot be attributed to a different level of depressive symptoms in this
population. Similar to what was discussed above regarding treatment effects on
depressive symptoms, any influence of smoking status on depressive symptoms may be
obscured by the impact of increased awareness, screening, and intervention targeting
perinatal psychological symptoms outside of this trial.
Despite a lack of difference between Dep+ and Dep- women on demand for
cigarettes, the CPT indices nevertheless provided significant predictive information
regarding the likelihood of quitting smoking in this sample of perinatal women. Baseline
CPT Intensity predicted abstinence rates independent of treatment condition. These
findings are consistent with other research showing that the CPT is a useful task for
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predicting smoking cessation in the general population (e.g., Gonzalez-Roz, 2019,
Higgins et al., 2017; MacKillop et al., 2016; Secades-Villa et al., 2016). In a systematic
literature review examining the sensitivity of hypothetical purchase tasks conducted by
our group (Zvorsky et al., under review), the CPT Intensity index was a significant
predictor of treatment response and one of the most sensitive indices for predicting other
substance-related correlates and outcomes. This study further validates the use of the
CPT in vulnerable populations of smokers, including socioeconomically disadvantaged
women of reproductive age and perinatal women (e.g., Higgins et al., 2017a; Higgins et
al., 2017b).
This study also examined the use of two measures of depressive symptoms in a
disadvantaged perinatal population. There was a difference in the number of women
categorized as depression-prone depending on which baseline score (the BDI or EPDS)
was utilized to account for current symptomatology. Thirty additional women, or 21% of
our study sample, were considered to have current symptoms according to the EPDS
using a cut point of 10 that were not categorized as having current symptoms by the BDI
using a cut point of 17. Ten is a validated and recommended cut point for the EPDS
screener (Cox et al., 1987) and 17 is a validated cut point for the BDI-1A (Beck & Steer,
1993). The number of women detected by the EPDS but not the BDI was reduced to 15
when a cut point of 10 was used for both instruments, to 3 when a cut point of 17 was
used for both, and finally to zero when the cut point was raised to 21. Of course, many
women would be excluded from further consideration of risk for perinatal depression if
the cut point was set to 21, which is an important potential limitation for screening
instruments (risk of inflated false-negatives).
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Literature on the relative specificity and sensitivity of the EPDS and BDI during
the perinatal is mixed. Some studies report that the EPDS is more sensitive and specific
than the BDI (e.g., Beck & Gable, 2001), although others report that the BDI has
acceptable sensitivity and specificity for use with perinatal women (Castro e Couto et al.,
2015; Ji et al., 2011). High rates of false positives have been noted for both measures;
however, these rates are expected considering that these measures are used as screeners
and are not intended to be diagnostic (Eberhard-Gran et al., 2017; Ji et al., 2011). Results
from the present study suggest that the two instruments produce relatively comparable
results when used with perinatal women and when cut points are comparable. However,
the EPDS is slightly more sensitive than the BDI, especially at lower cut points, and is
potentially more useful as a screening instrument in this population which is at elevated
risk for depression.
While limitations have been outlined above, a brief summary is warranted.
Namely, use of a different control condition may have obscured discerning potential
treatment effects on depressive symptoms, as women in the control condition for this
study reported similar changes in depressive symptoms throughout the trial. Further,
increased screening and intervention for perinatal symptoms may have acted as an
extraneous factor impacting symptoms in this trial and obscured potential treatment
effects. Finally, a diagnostic measure was not utilized, and this trial did not focus on a
clinical sample of perinatal women experiencing depressive symptoms. Future studies
should examine the impact of incentives targeting smoking cessation within a clinical
sample of women meeting diagnostic criteria for major depression disorder in the
perinatal to discern whether incentives reduce smoking in clinical samples and whether
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they differentially reduce depressive symptoms. Future studies should also gather
information about screening and intervention for perinatal distress to control for potential
effects. If the treatment effect on depressive symptoms is replicated, potential
mechanisms should be explored.
Conclusions
These limitations notwithstanding, financial incentives are an effective
intervention for smoking cessation in a disadvantaged perinatal population, even among
women endorsing current and historical depressive symptoms. While there were no
differences in the reinforcing value of cigarettes between Dep+ and Dep- women,
baseline Intensity, a measure of demand for cigarettes, significantly predicted smoking
abstinence after controlling for other predictors. This finding further highlights the utility
of hypothetical purchase tasks in detecting substance-related correlates and outcomes.
Financial incentives did not have any differential impact on depressive symptoms beyond
the control condition, differing from what has been observed in prior studies; although,
this may be attributable to the use of a different control condition and increased
awareness, screening, and intervention for perinatal mood disorders. Finally, the EPDS
and BDI appear to provide comparable and important screening information regarding
potential depression in socioeconomically disadvantaged perinatal women. When
differences between the two instruments were noted, the EPDS appeared to be more
sensitive than the BDI in detecting depressive symptoms.
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Table 1
Sociodemographic and Smoking Characteristics by Treatment Condition and Depression Risk Status
Incentives
Best Practices
Dep+
DepCharacteristic
(n = 81)
(n = 88)
(n = 91)
(n = 76)
Demographics:
25.4 ± 5.0
25.6 ± 5.1
Age (years)
26.6 ± 5.5
26.6 ± 5.4
Education
28
26
% <12 years
16
17
48
55
% 12 years
64
57
23
19
% >12 years
20
26
91
94
% Caucasian
93
91
16
20
% Married
20
17
27
23
% Private insurance
28
33
59
52
% Employed outside of home
50
59
53
47
% 1st pregnancy
42
47
12.4 ± 4.2
12.1 ± 4.3
Weeks pregnant at intake
11.1 ± 4.1
11.4± 4.0
28.2 ± 7.5
28.6 ± 8.4
Pre-pregnancy BMI
29.6 ± 8.4
29.5 ± 7.7
Smoking Characteristics:
19.2 ± 9.9
17.8 ± 9.7
Cigs/day pre-pregnancy
18.3 ± 9.4
20.0 ± 9.5
9.0 ± 5.2
9.1 ± 6.3
Cigs/day at 1 st AP assessment
9.9 ± 6.2
10.0 ± 5.0
15.1 ± 2.9
15.1 ± 3.2
Age started smoking (years)
15.5 ± 3.0
15.5 ± 2.6
% Living with other
smoker(s)
79
77
77
79
% With no smoking
allowed in home
68
70
68
72
% With none or few
friends/family who smoke
25
26
21
30
% Attempted to quit
pre-pregnancy
70
73
76
66
Number of quit attempts
during pregnancy
0.6 ± 1.0
0.7 ± 2.3
0.8 ± 2.3
0.4 ± 0.8
Nicotine withdrawal
questionnaire total score
1.4 ± 0.7
1.6 ± 0.7
1.8 ± 0.7***
1.1 ± 0.6
4.0 ± 2.1
4.0 ± 2.1
Fagerstrom score
4.2 ± 2.3
4.2 ± 2.2
Attitude Item:
% Endorsing that smoking
will greatly harm baby
85
81
82
83
Psychiatric Symptoms
5.0 ± 2.5***
6.4 ± 2.2***
Stress rating
6.3 ± 2.2
4.7 ± 2.4
10.0 ± 7.4*
15.8 ± 8.3***
BDI
12.8 ± 8.6
6.3 ± 3.7
% Ever having depressive
symptoms for 2+ weeks
42
52
88***
0
Note. M ± SD or %. Values were compared by treatment condition and by depression risk status.
* indicates p <.05; ** indicates p < .01; *** indicates p < .001. P-values are from ANOVAs for
continuous measures and chi-square or t-tests for categorical measures. Dep+ = depression-prone;
Dep- = depression negative; BMI = Body Mass Index; AP = antepartum; BDI = Beck Depression
Inventory.
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Table 2
Differences in baseline Cigarette Purchase Task indices by smoking status during pregnancy.
Early Pregnancy
Late Pregnancy
Smoking

Quit

Smoking

Quit

14.85**
CI [13.27*16.60]

10.76
CI [8.65-13.38]

15.56***
CI [13.95-17.35]

9.78
CI [7.96-12.02]

Omax

7.27
CI [6.24-8.48]

6.05
CI [4.24-8.62]

7.39
CI [6.40-8.53]

5.94
CI [4.06-8.67]

Pmax

0.95
CI [0.76-1.18]

0.92
CI [0.58-1.45]

0.94
CI [0.76-1.16]

0.96
CI [0.61- 1.51]

Breakpoint

1.46
CI [1.18-1.79]

1.40
CI [0.87-2.24]

1.46
CI [1.19-1.79]

1.41
CI [0.90-2.22]

Elasticity

0.01
CI [0.01-0.02]

1.46
CI [1.18-1.79]

0.01
CI [0.01-0.02]

0.02
CI [0.01-0.03]

Intensity

45

Note. * indicates p <.05; ** indicates p < .01; *** indicates p < .001.
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Table 3
Differences in baseline Cigarette Purchase Task indices by smoking status in the postpartum
2-weeks PP

4-weeks PP

8-weeks PP

12-weeks PP

24-weeks PP

50-weeks PP
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Smoking

Quit

Smoking

Quit

Smoking

Quit

Smoking

Quit

Smoking

Quit

Smoking

Quit

Intensity

15.46***
CI [13.8017.31]

10.67
CI [8.7912.95]

15.30**
CI [13.6517.15]

10.77
CI [8.8613.09]

15.34***
CI [13.7417.13]

10.24
CI [8.2412.73]

15.33***
CI [13.7517.10]

9.56
CI [7.6212.00]

14.67*
CI [13.1116.41]

10.84
CI [8.3414.10]

15.03
CI [13.3616.92]

11.30
CI [8.2615.44]

Omax

7.32
CI [6.308.52]

6.30
CI [4.568.68]

7.27
CI [6.268.45]

6.37
CI [4.568.89]

7.35
CI [6.278.60]

6.09
CI [4.428.40]

7.47
CI [6.408.73]

5.49
CI [3.887.76]

7.21
CI [6.168.43]

5.76
CI [3.888.55]

7.42
CI [86.298.76]

6.76
CI [4.1610.97]

Pmax

0.90
CI [0.731.12]

1.05
CI [0.691.60]

0.88
CI [0.711.09]

1.12
CI [0.721.74]

0.96
CI [0.771.21]

0.89
CI [0.591.34]

0.98
CI [0.781.22]

0.85
CI [0.561.29]

0.98
CI [0.791.23]

0.78
CI [0.491.23]

0.94
CI [0.751.19]

1.04
CI [0.532.03]

Breakpoint

1.37
CI [1.121.67]

1.65
CI [1.082.52]

1.41
CI [1.151.73]

1.54
CI [1.002.36]

1.52
CI [1.231.88]

1.25
CI [0.831.90]

1.53
CI [1.241.89]

1.20
CI [0.771.87]

1.55
CI [1.251.91]

1.13
CI [0.681.87]

1.50
CI [1.211.86]

1.40
CI [0.672.93]

Elasticity

0.01
CI [0.010.02]

0.01
CI [0.010.02]

0.01
CI [0.010.02]

0.01
CI [0.010.02]

0.01
CI [0.010.02]

0.01
CI [0.010.02]

0.01
CI [0.010.02]

0.01
CI [0.010.02]

0.01
CI [0.010.02]

0.01
CI [0.010.02]

0.01
CI [0.010.02]

0.01
CI [0.010.02]

Note. * indicates p <.05; ** indicates p < .01; *** indicates p < .001. PP= postpartum.
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Table 4
Main effects and interaction effects of smoking status and depression status on BDI scores
Depression
Smoking
Assessment
Status
p-value
Status
p-value
Interaction
p-value
df(3,147)
df(3,147)
df(3,147)
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Early
16.28****
< .0001
3.87
0.05
0.02
0.89
Pregnancy
Late
11.14***
0.001
0.62
0.43
1.64
0.20
Pregnancy
2-weeks PP
7.70**
0.006
2.24
0.14
2.31
0.13
4-weeks PP
7.82**
0.006
0.61
0.44
1.17
0.28
8-weeks PP
12.72***
0.0005
0.98
0.32
0.09
0.76
12-weeks
22.96****
< .0001
0.12
0.73
2.67
0.10
PP
24-weeks
12.01***
0.0007
0.45
0.50
0.35
0.55
PP
50-weeks
8.61**
0.004
1.46
0.23
1.42
0.24
PP
Note. Values represent F scores. * denotes p <.05; ** denotes p ≤ .01; *** denotes p ≤ .001;
****denotes p ≤ .0001. BDI= Beck Depression Inventory; PP= postpartum.
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Table 5

48

Main effects and interaction effects of smoking status and depression status on EPDS scores
Depression
Smoking
Assessment
Status
p-value
Status
p-value
Interaction
p-value
df(3,147)
df(3,147)
df(3,147)
Early
19.45****
<.0001
7.32**
0.008
0.83
0.36
Pregnancy
Late
13.18***
0.0004
1.98
0.16
0.74
0.39
Pregnancy
2-weeks PP
13.74***
0.0003
3.25
0.07
4.05
0.05
4-weeks PP
12.78***
0.0005
0.69
0.41
0.79
0.38
8-weeks PP
12.36***
0.0006
1.84
0.18
0.21
0.65
12-weeks
17.18****
<.0001
0.03
0.87
0.32
0.57
PP
24-weeks
11.38***
0.001
0.35
0.56
0.04
0.83
PP
50-weeks
12.01****
0.0008
0.07
0.79
4.09
0.06
PP
Note. Values represent F scores. * denotes p <.05; ** denotes p ≤ .01; *** denotes p ≤ .001;
****denotes p ≤ .0001. EPDS= Edinburgh Postnatal Depression Scale; PP= postpartum.
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Figure 1. Smoking abstinence rates by treatment condition across all assessments.
Note. * indicates p <.05; ** indicates p ≤ .01; *** indicates p ≤ .001; **** indicates p ≤ 0001. PP= postpartum.
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Figure 2. BDI scores by treatment condition across all assessments.
Note. * indicates p <.05; ** indicates p ≤ .01; *** indicates p ≤ .001; **** indicates p ≤ 0001. BDI=
Beck Depression Inventory; PP= postpartum.
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Figure 3. BDI scores by treatment condition and depression risk status across all assessments.
Note. * indicates p <.05; ** indicates p ≤ .01; *** indicates p ≤ .001; **** indicates p ≤ 0001.
BDI= Beck Depression Inventory; PP= postpartum; Dep+ = Depression-prone; Dep-= Depression-negative.
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Figure 4. EPDS scores by treatment condition across all assessments.
Note. * indicates p <.05; ** indicates p ≤ .01; *** indicates p ≤ .001; **** indicates p ≤
0001. EPDS= Edinburgh Postnatal Depression Scale; PP= postpartum.
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Figure 5. EPDS scores by treatment condition and depression risk status across all assessments.
Note. * indicates p <.05; ** indicates p ≤ .01; *** indicates p ≤ .001; **** indicates p ≤ 0001.
EPDS= Edinburgh Postnatal Depression Scale; PP= postpartum. Dep+= Depression-prone;
Dep- = Depression-negative.
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Figure 6. BDI scores by treatment condition and depression risk status as defined by the EPDS across all assessments.
Note. * indicates p <.05; ** indicates p ≤ .01; *** indicates p ≤ .001; **** indicates p ≤ 0001. BDI= Beck Depression
Inventory; PP= postpartum. DepE+= Depression-prone defined by EPDS;
DepE- = Depression-negative defined by EPDS.
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Figure 7. EPDS scores by treatment condition and depression risk status as defined by the EPDS across all assessments.
Note. * indicates p <.05; ** indicates p ≤ .01; *** indicates p ≤ .001; **** indicates p ≤ 0001. EPDS= Edinburgh Postnatal
Depression Scale; PP= postpartum. DepE+= Depression-prone defined by EPDS;
DepE- = Depression-negative defined by EPDS.
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